North Carolina State University

Ritter Pharmaceuticals, Inc.

Northwestern University

The United States of America As Represented by the Secretary of

University of Virginia Patent Foundation

Todd Robert Klaenhammer

W Michael Russell

David M Barnes

Andrew J Ritter

Eric Altermann

Dennis Savaiano

Rodolphe Barrangou

Eric Heinz Altermann

Andrea Azcarate-Peril

Tri Duong

William Michael Russell

B Logan Buck

Rosemary B Sanozky

Sylvain Moineau

Mansour Mohamadzadeh

Erika Pfeiler

Evelyn Durmaz

Eric R Altermann

Larry R Steenson

Colin J Hill

Mark A Conkling

Richard Littleton Guerrant

Michael Paul Timko

Shirley A Walker

Henry P Fleming

Cirle Alcantara Warren

Wesley D Sing

Christopher G Taylor

Gordana Djordjevic

Dan O'Sullivan

M Andrea Azcarate-Peril

Mark A Daeschel

Roger F McFeeters

Olivia McAuliffe

Rosemary B Sanozky-Dawes

Glynis L Kolling

Joseph Miland Sturino

Martin J Kullen

Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.

Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.

Prebiotic formulations and methods of use

The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.

Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitivebacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by thebacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject abacterium modified to release a biotherapeutic agent following bile exposure. Administration of thebacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders includinginfection and antibiotic-associated diarrhea.

[object Object]

Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.

NCFM nucleic acid molecules, polypeptides, fragments and variants thereof are provided in the current invention. In addition, fusion proteins, antigenic peptides, and antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells comprising the expression vectors. Methods for producing the polypeptides of the invention and methods for their use are further provided.

Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.

Growing community of inventors

Raleigh, NC, United States of America

Todd Robert Klaenhammer